Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of TGRX-326 in Healthy Chinese Males
NCT06438367Phase 1Completed
- Sponsor
- Shenzhen TargetRx
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deulorlatinib in non-small cell lung cancer (NSCLC), sponsored by Shenzhen TargetRx. Primary endpoints: Urine radioactivity, Fecal radioactivity and 5 more. Started Jun 2024; status: completed.
02
Drugs
deulorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06438367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06438367.